Natalizumab and central nervous system lymphoma: no clear association.
Carmen
C
Bozic
Julia
J
LaGuette
Michael A
MA
Panzara
Alfred W
AW
Sandrock
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D016543:Central Nervous System Neoplasms / Q000139:chemically induced / Q000453:epidemiology; D006801:Humans; D008223:Lymphoma / Q000139:chemically induced / Q000453:epidemiology; D009103:Multiple Sclerosis / Q000188:drug therapy; D000069442:Natalizumab; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab